- Home
- OSUR vs AVIR Comparison
OSUR vs AVIR Comparison
Compare OSUR & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OSUR | AVIR |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.2M | 236.7M |
| IPO Year | 1986 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OSUR | AVIR |
|---|---|---|
| Price | $2.43 | $3.66 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 1 |
| Target Price | $3.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 676.8K | 364.0K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $125,703,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.08 | $2.46 |
| 52 Week High | $4.22 | $4.02 |
Technical Indicators
Market Signals| Indicator | OSUR | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 73.01 |
| Support Level | $2.41 | $3.11 |
| Resistance Level | $2.49 | $3.27 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 27.12 | 88.52 |
Price Performance
Historical ComparisonAbout OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).